Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis

Shiva Kumar; Songhua Lin; Jesse D Schold

doi:10.1007/s12072-024-10733-y

Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis

Hepatol Int. 2024 Oct 30. doi: 10.1007/s12072-024-10733-y. Online ahead of print.

Authors

Shiva Kumar¹, Songhua Lin², Jesse D Schold³

Affiliations

¹ Department of Gastroenterology and Hepatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. kumars5@clevelandclinicabudhabi.ae.
² Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA.
³ Departments of Surgery and Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

PMID: 39476285
DOI: 10.1007/s12072-024-10733-y

Abstract

Background: Limited data exists regarding impact of graft type on outcomes following liver transplantation (LT) in Primary Sclerosing Cholangitis (PSC). Our goal was to evaluate the impact of graft type on outcomes following LT in PSC and determine predictors of outcomes.

Methods: Using the Scientific registry of transplant recipients (SRTR), retrospective cohorts were constructed of recipients with PSC over the time period 2010-2020, divided into 2 eras: 2010-2014, 2015-2020, stratified by graft type: living donor (LDLT), donation after circulatory death (DCD) and donation after brain death (DBD). Outcome measures evaluated were graft and patient survival. Survival comparison was performed using Kaplan-Meier method and multivariable analysis using Cox proportional hazard models.

Results: 2966 recipients underwent LT for PSC over the study period: LDLT-PSC 153 (5.2%), DCD-PSC 131 (4.4%) and DBD-PSC 2682 (90.4%). While LDLT utilization was higher in PSC (5.2% vs. 1.3%; p < 0.001), DCD use was lower (4.4% vs. 7.2%; p < 0.001) but increased over time (era 1 vs. era 2: 3.3% vs. 5.2%; p = 0.02). Outcomes following DCD-PSC were comparable to DBD and improved over time. Compared to DBD-PSC, there was a trend toward lower short-term graft survival following LDLT-PSC (1 Yr. 85.3 vs. 91.9; p = 0.07) with higher retransplant rate (LDLT-PSC vs. DCD-PSC vs. DBD-PSC: 15% vs 11% vs 7%; p < 0.001). Compared to recipients without PSC, long-term patient survival was superior in LDLT-PSC (5 Yr. 90.1 vs. 83.7%; p = 0.05) and DCD-PSC (93.3 vs. 79.7%, p = 0.01). On multivariable analysis, LDLT but not DCD graft type, was associated with inferior graft survival in PSC (adjusted hazard Ratio = 1.65 (1.16-2.34); p = 0.005).

Conclusions: In PSC, utilization of LDLT is higher, while DCD use is lower but increased over time. Outcomes following DCD LT in PSC are comparable to DBD and superior to recipients without PSC. Reduced graft survival and higher re-transplant rate following LDLT in PSC warrants further study. Consideration of DCD could help expand the donor pool in PSC.

Keywords: Donation after brain death; Donation after circulatory death; Graft survival; Living donor liver transplant; Patient survival; Primary sclerosing cholangitis.